<DOC>
	<DOCNO>NCT02476019</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics ISIS-FGFR4RX .</brief_summary>
	<brief_title>A Safety , Tolerability , PK , PD Study Once Weekly ISIS-FGFR4RX SC Obese Patients</brief_title>
	<detailed_description />
	<criteria>1 . Must give write informed consent ( sign date ) authorization require local law able comply study requirement 2 . Male female patient age 1865 year , inclusive Females : Must postmenopausal ( defined 12 month spontaneous amenorrhea female &gt; 55 year age , females â‰¤ 55 year , 12 month spontaneous amenorrhea without alternative medical cause FSH level postmenopausal range laboratory involve ) Males : Surgically sterile , abstinent engage sexual relation woman childbearing potential , patient utilize acceptable contraceptive method 5 month last dose ISIS 463588 placebo ( Study Drug ) 3 . Body Mass Index ( BMI ) 30.0 40.0 kg/m2 , inclusive 4 . Patients willing comply schedule visit , treatment plan , laboratory test study procedure 5 . Agree abstain alcoholic beverage least 48 hour prior clinic visit 6 . Agree maintain current diet exercise regimen Screening EndofStudy 1 . Clinically significant abnormality medical history ( e.g. , previous acute coronary syndrome within 6 month Screening , major surgery within 3 month Screening ) physical examination 2 . Positive test HIV , hepatitis B C Screening 3 . Hypothyroidism Hyperthyroidism 4 . Weight change &gt; 5 % 3 month prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Energy Expenditure</keyword>
</DOC>